title: Carboplatin plus paclitaxel for advanced or recurrent uterine malignant mixed mullerian tumors. The British Columbia Cancer Agency experience.
abstract: OBJECTIVE
  Uterine MMMTs are aggressive malignancies that are rarely cured by purely local therapies. Effective chemotherapy is needed. The phase III proven, ifosfamide-based combinations are inconvenient and costly. Carboplatin and paclitaxel (CT) are easy to deliver and is effective against endometrial carcinoma and should be against MMMT (as they are now regarded as epithelial in nature).
  
  
  METHODS
  A review of all women with uterine MMMT treated with CT. Paclitaxel 175 mg/m2 over 3 h preceded carboplatin (AUC 5-6) every 4 weeks for 3-6 cycles+/-subsequent pelvic irradiation.
  
  
  RESULTS
  Twenty-eight newly diagnosed women (20 evaluable) and 12 recurrent (11 evaluable) were treated. Response rates were 60% (12 of 20, CR 5, PR 7) and 55% (6 of 11, CR 2, PR 4) with median PFS of 16 and 12 months. Dose reduction occurred in 5%, treatment delay in 10%.
  
  
  CONCLUSIONS
  Carboplatin-paclitaxel is effective against uterine MMMT, with similar efficacy to ifosfamide combinations. It is more convenient, less costly and easy to deliver.
authors.affiliation: Division of Medical Oncology, Vancouver Cancer Centre, Vancouver, BC, Canada. phoskins@bccancer.bc.ca
authors.forename: Paul J
authors.initials: PJ
authors.lastname: Hoskins
authors.forename: Nhu
authors.initials: N
authors.lastname: Le
authors.forename: Susan
authors.initials: S
authors.lastname: Ellard
authors.forename: Ursula
authors.initials: U
authors.lastname: Lee
authors.forename: Lee Ann
authors.initials: LA
authors.lastname: Martin
authors.forename: Kenneth D
authors.initials: KD
authors.lastname: Swenerton
authors.forename: Anna V
authors.initials: AV
authors.lastname: Tinker
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D016190:Carboplatin / Q000008:administration & dosage; D003131:Combined Modality Therapy; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D008875:Middle Aged; D018200:Mixed Tumor, Mullerian / Q000188:drug therapy* / Q000473:pathology; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy* / Q000473:pathology; D009367:Neoplasm Staging; D017239:Paclitaxel / Q000008:administration & dosage; D012189:Retrospective Studies; D014594:Uterine Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery
chemical_list: D016190:Carboplatin; D017239:Paclitaxel